Bright Minds Biosciences Inc. (DRUG) Advances Phase 2 Trial for Drug-Resistant Epilepsy
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a biotechnology company developing highly selective 5-HT2 agonists to treat drug-resistant epilepsy, depression, and other CNS disorders.
Hedge Fund Resource Center
